New Version of the Q&A Catalogue published

Recommendation
30 June 2025
Again, the question and answer catalogue "QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC" of the Heads of Medicines Agencies (HMA), European Medicines Agency (EMA) and the European Commission (EC) has been extended and updated. This third version additionally lists points 4.2-4.4 and includes an update of point 2.2.
The question and answer catalogue provides instructions on the current handling of marketing authorisation procedures and existing marketing authorisations and informs about the handling of variation procedures or marketing authorisation renewals. Additional guidance and practical approaches to these issues can be found in the "Practical guidance of the CMDh for facilitating the handling of processes during the COVID-19 crisis".
Here, you will find the latest version of the "QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC" and the corresponding explanations of "Practical guidance of the CMDh for facilitating the handling of processes during the COVID-19 crisis".
Related GMP News
04.06.2025EDQM: Update of Guideline "How to read a CEP"
16.04.2025EMA: Revised IRIS Documents
09.04.2025Centralised Procedures: Q&As Updated
12.03.2025CMDh/HMA: Guidance Documents on Variation Notifications Updated
11.03.2025EMA: Renewal of Q&A Document for "Centralized Procedures"
11.03.2025Centralised Procedures: Q&A Documents also Updated for Biosimilars